The Role of Antifungals Against Candida Biofilm in Catheter-Related Candidemia

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2016 Mar 31

PMID 27025612

Citations 21

Authors

Emilio Bouza

Jesus Guinea

Maria Guembe

Affiliations

Soon will be listed here.

Abstract

Catheter-related bloodstream infection (C-RBSI) is one of the most frequent nosocomial infections. It is associated with high rates of morbidity and mortality. Candida spp. is the third most common cause of C-RBSI after coagulase-negative staphylococci and Staphylococcus aureus and is responsible for approximately 8% of episodes. The main cause of catheter-related candidemia is the ability of some Candida strains-mainly C. albicans and C. parapsilosis-to produce biofilms. Many in vitro and in vivo models have been designed to assess the activity of antifungal drugs against Candida biofilms. Echinocandins have proven to be the most active antifungal drugs. Potential options in situations where the catheter cannot be removed include the combination of systemic and lock antifungal therapy. However, well-designed and -executed clinical trials must be performed before firm recommendations can be issued.

Citing Articles

State of the Globe: Catheter-Related Persistent Candida Infections after Candida Catheter-Related Bloodstream Infection.

Kumar N, Snitowsky R J Glob Infect Dis. 2024; 16(3):83-84.

PMID: 39619373 PMC: 11606544. DOI: 10.4103/jgid.jgid_183_24.

Clinical Features of Catheter-related Bloodstream Infections and Persistent Infections Associated with Early Catheter Reinsertion: A 6-year Retrospective Study.

Kobayashi T, Nakamura I, Machida M, Watanabe H J Glob Infect Dis. 2024; 16(3):85-91.

PMID: 39619369 PMC: 11606547. DOI: 10.4103/jgid.jgid_17_24.

Biofilm formation and drug susceptibility of biofilm spp. clinically isolated from nasopharyngeal cancer patients in Vietnam.

Nguyen B, Tran L, Vo T, Nguyen-Ha A, Le M, Nguyen P Iran J Microbiol. 2024; 16(5):698-707.

PMID: 39534299 PMC: 11551658. DOI: 10.18502/ijm.v16i5.16806.

Amphotericin B in the Era of New Antifungals: Where Will It Stand?.

Akinosoglou K, Rigopoulos E, Papageorgiou D, Schinas G, Polyzou E, Dimopoulou E J Fungi (Basel). 2024; 10(4).

PMID: 38667949 PMC: 11051097. DOI: 10.3390/jof10040278.

Contribution of -Linked Mannosylation Pathway to and Biofilm Formation.

Clavijo-Giraldo D, Perez-Garcia L, Hernandez-Chavez M, Martinez-Duncker I, Mora-Montes H Infect Drug Resist. 2023; 16:6843-6857.

PMID: 37908782 PMC: 10614665. DOI: 10.2147/IDR.S431745.

References

Raad I, Rosenblatt J, Reitzel R, Jiang Y, Dvorak T, Hachem R . Chelator-based catheter lock solutions in eradicating organisms in biofilm. Antimicrob Agents Chemother. 2012; 57(1):586-8. PMC: 3535935. DOI: 10.1128/AAC.01287-12. View

Leon C, Alvarez-Lerma F, Ruiz-Santana S, Gonzalez V, de la Torre M, Sierra R . Antiseptic chamber-containing hub reduces central venous catheter-related infection: a prospective, randomized study. Crit Care Med. 2003; 31(5):1318-24. DOI: 10.1097/01.CCM.0000026327.58305.22. View

Walraven C, Lee S . Antifungal lock therapy. Antimicrob Agents Chemother. 2012; 57(1):1-8. PMC: 3535896. DOI: 10.1128/AAC.masthead.57-1. View

Alexander Blackwood R, Klein K, Micel L, Willers M, Mody R, Teitelbaum D . Ethanol locks therapy for resolution of fungal catheter infections. Pediatr Infect Dis J. 2011; 30(12):1105-7. DOI: 10.1097/INF.0b013e31822c84a4. View

Oncu S . In vitro effectiveness of antifungal lock solutions on catheters infected with Candida species. J Infect Chemother. 2011; 17(5):634-9. DOI: 10.1007/s10156-011-0224-3. View

Brass E, Edwards J . Should the guidelines for management of central venous catheters in patients with candidemia be changed now?. Clin Infect Dis. 2010; 51(3):304-6. DOI: 10.1086/653936. View

Uppuluri P, Lopez-Ribot J . An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence. 2010; 1(6):483-7. PMC: 3073357. DOI: 10.4161/viru.1.6.13186. View

Buckler B, Sams R, Goei V, Krishnan K, Bemis M, Parker D . Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J. 2008; 27(8):762-4. DOI: 10.1097/INF.0b013e318170b68b. View

Kucharikova S, Sharma N, Spriet I, Maertens J, Van Dijck P, Lagrou K . Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model. Antimicrob Agents Chemother. 2013; 57(5):2365-8. PMC: 3632894. DOI: 10.1128/AAC.02288-12. View

10.

ARNOW P, Kushner R . Malassezia furfur catheter infection cured with antibiotic lock therapy. Am J Med. 1991; 90(1):128-30. DOI: 10.1016/0002-9343(91)90518-3. View

11.

Weinberger M, Leibovici L, Perez S, Samra Z, Ostfeld I, Levi I . Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect. 2005; 61(2):146-54. DOI: 10.1016/j.jhin.2005.02.009. View

12.

Melo A, Bizerra F, Freymuller E, Arthington-Skaggs B, Colombo A . Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol. 2010; 49(3):253-62. DOI: 10.3109/13693786.2010.530032. View

13.

Hornby J, Jensen E, Lisec A, Tasto J, Jahnke B, Shoemaker R . Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol. 2001; 67(7):2982-92. PMC: 92970. DOI: 10.1128/AEM.67.7.2982-2992.2001. View

14.

Krzywda E, Andris D, Edmiston Jr C, Quebbeman E . Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol. 1995; 16(10):596-8. DOI: 10.1086/647015. View

15.

Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T . Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008; 27(9):820-6. DOI: 10.1097/INF.0b013e31817275e6. View

16.

Ferreira J, Carr J, Starling C, de Resende M, Donlan R . Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother. 2009; 53(10):4377-84. PMC: 2764222. DOI: 10.1128/AAC.00316-09. View

17.

Donlan R . Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis. 2001; 33(8):1387-92. DOI: 10.1086/322972. View

18.

Samore M, Burke J . Infections of long intravenous lines: new developments and controversies. Curr Clin Top Infect Dis. 2000; 20:256-70. View

19.

Ricicova M, Kucharikova S, Tournu H, Hendrix J, Bujdakova H, Van Eldere J . Candida albicans biofilm formation in a new in vivo rat model. Microbiology (Reading). 2009; 156(Pt 3):909-919. DOI: 10.1099/mic.0.033530-0. View

20.

Jacobson M, Piper K, Nguyen G, Steckelberg J, Patel R . In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2008; 52(6):2242-3. PMC: 2415795. DOI: 10.1128/AAC.00211-08. View